PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.98%
Revenue growth similar to AVGO's 6.80%. Walter Schloss would see if both companies share industry tailwinds.
7.66%
Gross profit growth at 50-75% of AVGO's 12.88%. Martin Whitman would question if cost structure or brand is lagging.
11.16%
EBIT growth below 50% of AVGO's 25.00%. Michael Burry would suspect deeper competitive or cost structure issues.
10.84%
Operating income growth under 50% of AVGO's 25.00%. Michael Burry would be concerned about deeper cost or sales issues.
11.70%
Net income growth under 50% of AVGO's 36.67%. Michael Burry would suspect the firm is falling well behind a key competitor.
12.70%
EPS growth under 50% of AVGO's 34.21%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
14.52%
Diluted EPS growth under 50% of AVGO's 35.14%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-1.99%
Share reduction while AVGO is at 0.42%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-2.05%
Reduced diluted shares while AVGO is at 0.41%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.75%
Dividend reduction while AVGO stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
134.52%
OCF growth above 1.5x AVGO's 19.13%. David Dodd would confirm a clear edge in underlying cash generation.
230.47%
FCF growth above 1.5x AVGO's 18.56%. David Dodd would verify if the firm’s strategic investments yield superior returns.
72.02%
10Y revenue/share CAGR above 1.5x AVGO's 12.18%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
42.89%
5Y revenue/share CAGR above 1.5x AVGO's 12.18%. David Dodd would look for consistent product or market expansions fueling outperformance.
22.19%
3Y revenue/share CAGR above 1.5x AVGO's 12.18%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
292.55%
10Y OCF/share CAGR above 1.5x AVGO's 104.45%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
19.41%
Below 50% of AVGO's 104.45%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
3.03%
3Y OCF/share CAGR under 50% of AVGO's 104.45%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
83.88%
Net income/share CAGR at 50-75% of AVGO's 150.30%. Martin Whitman might question if the firm’s product or cost base lags behind.
86.72%
5Y net income/share CAGR at 50-75% of AVGO's 150.30%. Martin Whitman might see a shortfall in operational efficiency or brand power.
32.48%
Below 50% of AVGO's 150.30%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
16.38%
Equity/share CAGR of 16.38% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
15.09%
Equity/share CAGR of 15.09% while AVGO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
7.05%
Equity/share CAGR of 7.05% while AVGO is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
493.84%
Dividend/share CAGR of 493.84% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
784467.57%
Dividend/share CAGR of 784467.57% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
50.12%
3Y dividend/share CAGR of 50.12% while AVGO is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
2.27%
AR growth is negative/stable vs. AVGO's 12.05%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
5.56%
Inventory growth well above AVGO's 3.93%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
3.99%
Asset growth at 50-75% of AVGO's 7.74%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
4.19%
Under 50% of AVGO's 10.62%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
No Data
No Data available this quarter, please select a different quarter.
6.38%
R&D growth drastically higher vs. AVGO's 1.43%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
3.44%
SG&A growth well above AVGO's 6.25%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.